TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04425174

Intervention type: PROCEDURE
Intervention: Quadratous lumborum block
Description: Quadratus Lumborum (QL) block is a new technique for analgesia of the abdominal wall muscles. Its mechanism depends on the injection of the local anesthetic agent between the abdominal wall muscles into the thoracolumbar fascia surrounding the Quadratus Lumborum muscle by ultrasound (US) guided technique.

Intervention type: PROCEDURE
Intervention: Epidural anesthesia
Description: Epidural analgesia is a gold standard analgesic technique for the majority of abdominal surgeries, yet it has some limitations in some surgeries as colorectal surgeries due to delayed ambulation due to muscular weakness and postural hypotension.
Study: NCT02908503

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Film
Description: placebo vaginal films

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Film
Description: placebo vaginal films

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Film
Description: placebo vaginal films

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Film
Description: placebo vaginal films
Study: NCT03180151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piezotome assisted orthodontic tooth movement
Description: Surgical procedure~1. After local anesthesia, vertical interproximal incisions will be done under the interdental papilla, on the labial aspect of upper arch using a blade No. 15.~2. The incisions will be kept minimal.~3. The incisions go though the periosteum, which permit the blade to reach to the alveolar bone.~4. A Piezo surgical knife will be used to make the cortical alveolar incision through the gingival incisions to a depth of approximately 3mm.~5. As we will not use bone graft so we don't need use suturing after cortication.~6. We give patient antibiotic and analgesic cover.
Study: NCT03796429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS+Toripalimab
Description: Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab（240mg, iv, q3w），combined with GS regimen(gemcitabine 1000mg／m2 ，d1,d8 + S1 40-60mg bid\*14d，Q21d).~The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years).
Study: NCT04341454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 X mg
Description: DWP14012 X mg, tablet, orally, once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 X mg placebo
Description: DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP14012 X mg placebo
Description: DWP14012 X mg placebo-matching tablet, orally, once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 Y mg
Description: DWP14012 Y mg, tablet, orally, twice daily for 2 weeks
Study: NCT00392899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFT adjuvant chemotherapy
Description: UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
Study: NCT00779194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin, is given to this group at a starting dose of 2 mg/day.
Study: NCT04341454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 Y mg placebo
Description: DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP14012 Y mg placebo
Description: DWP14012 Y mg placebo-matching tablet, orally, twice daily for 2 weeks
Study: NCT03272490

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medartis
Description: Surgery using the medartis implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Synthes
Description: Surgery using the Synthes implant
Study: NCT02231333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxiphylline (PTX)
Study: NCT01817621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Intervention
Description: The experimental intervention arm will include the same measures as the TAU comparison study arm. In addition, participants will attend several sessions addressing body dissatisfaction, including psychoeducation on the antecedents and consequences of body dissatisfaction, the common comorbidity of depressed mood, and how these factors can affect HIV self-care behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Participants assigned to the TAU condition will receive appropriate services and referrals as needed, as would be typical of patients at Fenway Health or MGH, and will attend bi-weekly appointments with a study research assistant (RA) to complete study questionnaires and assess pocketed adherence, including HAART doses that participants may have taken outside of Wisepill.
Study: NCT02594709

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multisession Radiosurgery
Description: Patients will undergo multisession radiosurgery as clinical practice.
Study: NCT02481804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Patients will be counseled by a dietician for 14 weeks. A tailored diet advice for each NET patient will be based on the individual situation which includes gastrointestinal complaints, the location of the tumor, additional treatments like previous surgery and measured vitamine and tryptophan levels.~Dietician consults will be conducted by 1 out-patient visit and 3 follow up contacts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment will be continued
Study: NCT00372476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib and Vinorelbine
Study: NCT00703391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 30mg oral tablets twice daily (bid) for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
Study: NCT06432257

Intervention type: DEVICE
Intervention: head mounted magnifying glass assistance
Description: When performing thyroid surgery for patients in the experimental group, the surgeon uses a head mounted magnifying glass for assistance
Study: NCT03607591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: rTMS is a non-invasive and safe brain stimulation technique, that uses a magnetic pulse, administrated through a coil, set on the DLPFC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rTMS
Description: rTMS is a non-invasive and safe brain stimulation technique, that uses a magnetic pulse, administrated through a coil, set on the DLPFC
Study: NCT03989388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational self-analysis
Description: The Occupational Self-Analysis program provides participants with a space where they can learn to analyse the barriers and supports for occupational participation.
Study: NCT03210597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The subjects performed training in aquatic environment
Study: NCT03989388

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vocational guidance
Description: To explore participant´s job interests and learned how to find a job and define a professional profile.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Rehabilitation
Description: Usual rehabilitation: occupational therapy and/or physiotherapy.
Study: NCT01212913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily
Study: NCT02869802

Intervention type: PROCEDURE
Intervention: Tumour Biopsy
Description: If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.

Intervention type: OTHER
Intervention: Serial Collection of Plasma and Serum Samples
Description: Participants will undergo serial collection of plasma and serum samples at baseline and every 4 weeks until end of study.

Intervention type: OTHER
Intervention: Serial Collection of Plasma and Serum Samples
Description: Participants will undergo serial collection of plasma and serum samples at baseline and every 4 weeks until end of study.
Study: NCT00779805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine hydrochloride 120 mg ER tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine hydrochloride 120 mg ER tablets
Study: NCT00772902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada + Kaletra
Description: Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kivexa + Kaletra
Description: Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
Study: NCT01201837

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CER-001
Description: Weekly injection
Study: NCT01201837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CER-001
Description: Weekly injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CER-001
Description: Weekly injection
Study: NCT03253250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ETV；TDF；ADV
Description: NAs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV；TDF；ADV
Description: NAs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: peginterferon
Study: NCT00687869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management
Description: Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management
Description: Usual stroke aftercare plus patient-information-notes
Study: NCT01489774

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single and multiple dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12406
Description: single and multiple dose
Study: NCT02766725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preparation F12 sildenafil in situ gel
Description: in situ vaginal gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: preparation F2 sildenafil in situ gel
Description: in situ vaginal gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: vaginal gel
Study: NCT03912116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLARIX FLO
Description: 100mg CLARIX FLO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study: NCT03259204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjuvant IPC
Description: This IPC-system delivers sequential circumferential compression. The IPC device is mobile and should therefore not restrict patient mobilization, but can be taken off if the patient wants to mobilize independently.
Study: NCT03544502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CD player
Description: CD player opened during anesthesia induction and continued until postoperative 15 minute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEL-480 Sound Level Meter Sonometre
Description: Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CEL-480 Sound Level Meter Sonometre
Description: Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEL-480 Sound Level Meter Sonometre
Description: Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Earplug
Description: the independent anesthesiologist placed earplug into the patients' ears during anesthesia induction and the ear plug were removed immediately before tracheal tube extubation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ambient operating room noise
Description: patients were exposed to the ambient operating room noise.
Study: NCT03735225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Dasiglucagon injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Dasiglucagon injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Dasiglucagon injection
Study: NCT02822768

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Packing
Description: The patient will receive packing as part of their wound care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No packing
Description: The patient will not receive packing as part of their wound care
Study: NCT04698902

Intervention type: DEVICE
Intervention: Intracoronary lithotripsy
Description: Intracoronary lithotripsy involves the use of sonic pressure waves generated from emitters enclosed within a balloon delivery system. The generated sonic waves act to fracture calcium within the coronary artery wall.

Intervention type: DEVICE
Intervention: Intracoronary lithotripsy
Description: Intracoronary lithotripsy involves the use of sonic pressure waves generated from emitters enclosed within a balloon delivery system. The generated sonic waves act to fracture calcium within the coronary artery wall.

Intervention type: DEVICE
Intervention: Intracoronary lithotripsy
Description: Intracoronary lithotripsy involves the use of sonic pressure waves generated from emitters enclosed within a balloon delivery system. The generated sonic waves act to fracture calcium within the coronary artery wall.
Study: NCT00707824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nalbuphine
Description: nalbuphine 5 mg epidural

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nalbuphine
Description: nalbuphine 10 mg epidural

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: NSS
Study: NCT01026467

Intervention type: DRUG
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Intervention: carboplatin
Description: Given IV

Intervention type: OTHER
Intervention: questionnaire administration
Study: NCT02229747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimesulide
Study: NCT00296374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg oral dose administered once daily for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
Study: NCT01721330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Up to 100mg of Naltrexone once a day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day for 6 weeks
Study: NCT03680573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control: Lacated Ringers
Description: This site will serve as the control site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apocynin
Description: This site will be used to inhibit NADPH oxidase and subsequent production of superoxide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: This site will be use to inhibit xanthine oxidase and subsequent production of superoxide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BH4
Description: This site will be use to locally supplement BH4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
Study: NCT02158806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 150 mg aspirin in capsule form once daily for up to 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsule containing inert bulking agent
Study: NCT03680573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-ß-methylcholine chloride
Description: Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-ß-methylcholine chloride
Description: Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-ß-methylcholine chloride
Description: Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-ß-methylcholine chloride
Description: Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
Study: NCT00426491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: 400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
Study: NCT04342364

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitrification via slush nitrogen
Description: oocytes will be vitrified using slush nitrogen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitrification via liquid nitrogen
Description: oocytes will be vitrified using liquid nitrogen which is currently routine practice
Study: NCT04486820

Intervention type: OTHER
Intervention: Analysis Immunohistochemical
Description: Analysis of histological material for immunohistochemical study. To explore PD-L1, CD8, CDX2, INSM1 and FOXA1 expression
Study: NCT03280511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC
Description: PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 46 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
Study: NCT02610322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole soy replacement diet
Description: Participants who are allocated to Whole soy group will receive a 30\~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products